MX2011007188A - Metodos para incrementar niveles de plasmalogenos endogenos. - Google Patents

Metodos para incrementar niveles de plasmalogenos endogenos.

Info

Publication number
MX2011007188A
MX2011007188A MX2011007188A MX2011007188A MX2011007188A MX 2011007188 A MX2011007188 A MX 2011007188A MX 2011007188 A MX2011007188 A MX 2011007188A MX 2011007188 A MX2011007188 A MX 2011007188A MX 2011007188 A MX2011007188 A MX 2011007188A
Authority
MX
Mexico
Prior art keywords
methods
endogenous plasmalogen
increasing endogenous
plasmalogen levels
levels
Prior art date
Application number
MX2011007188A
Other languages
English (en)
Spanish (es)
Inventor
Frederic Destaillats
Cristina Cruz-Hernandez
Jean-Baptiste Bezelgues
Fabiola Dionisi
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of MX2011007188A publication Critical patent/MX2011007188A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fodder In General (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Feed For Specific Animals (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
MX2011007188A 2009-01-02 2009-12-30 Metodos para incrementar niveles de plasmalogenos endogenos. MX2011007188A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20417009P 2009-01-02 2009-01-02
PCT/US2009/006749 WO2010077358A1 (en) 2009-01-02 2009-12-30 Methods for increasing endogenous plasmalogen levels

Publications (1)

Publication Number Publication Date
MX2011007188A true MX2011007188A (es) 2011-09-01

Family

ID=42310073

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011007188A MX2011007188A (es) 2009-01-02 2009-12-30 Metodos para incrementar niveles de plasmalogenos endogenos.

Country Status (10)

Country Link
US (1) US20110275600A1 (https=)
EP (1) EP2373161A4 (https=)
JP (1) JP2012514597A (https=)
CN (1) CN102271502A (https=)
AU (1) AU2009333809A1 (https=)
CA (1) CA2747582A1 (https=)
MX (1) MX2011007188A (https=)
RU (1) RU2011132386A (https=)
WO (1) WO2010077358A1 (https=)
ZA (1) ZA201105665B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010100060A2 (en) * 2009-03-04 2010-09-10 Nestec S.A. Method for increasing endogenous plasmalogen levels in mammals
CN103314291B (zh) * 2010-12-28 2016-05-11 藤野脑研究株式会社 通过血液样品判定痴呆症用的检验方法
JP5934483B2 (ja) * 2011-09-05 2016-06-15 学校法人帝京大学 リン脂質結合型ｄｈａ増加剤
JP5997887B2 (ja) * 2011-09-05 2016-09-28 学校法人帝京大学 経口投与剤
JP7704407B2 (ja) * 2021-08-04 2025-07-08 株式会社 レオロジー機能食品研究所 がん治療用組成物
JP2023108631A (ja) * 2022-01-26 2023-08-07 大道 藤本 ドッグフード

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050027004A1 (en) * 1993-06-09 2005-02-03 Martek Biosciences Corporation Methods of treating senile dementia and Alzheimer's diseases using docosahexaenoic acid and arachidonic acid compositions
US20070004670A1 (en) * 1998-07-31 2007-01-04 Richard Wurtman Compositions containing citicoline, and methods of use thereof
US8052992B2 (en) * 2003-10-22 2011-11-08 Enzymotec Ltd. Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions
US20080033027A1 (en) * 2005-03-21 2008-02-07 Vicus Therapeutics Spe 1, Llc Drug combination pharmaceutical compositions and methods for using them
US20080044487A1 (en) * 2006-05-05 2008-02-21 Natural Asa Anti-inflammatory properties of marine lipid compositions
JP5220842B2 (ja) * 2007-04-13 2013-06-26 フェノメノーム ディスカバリーズ インク プラスマロゲン欠乏症が媒介する加齢に伴う疾患の診断及びリスク評価のための方法

Also Published As

Publication number Publication date
WO2010077358A1 (en) 2010-07-08
CN102271502A (zh) 2011-12-07
RU2011132386A (ru) 2013-02-10
US20110275600A1 (en) 2011-11-10
EP2373161A4 (en) 2012-05-30
EP2373161A1 (en) 2011-10-12
ZA201105665B (en) 2013-01-30
JP2012514597A (ja) 2012-06-28
AU2009333809A1 (en) 2011-07-14
CA2747582A1 (en) 2010-07-08

Similar Documents

Publication Publication Date Title
MX2011013421A (es) Arnds formulado con lipido de direccionamiento del gen pcsk9.
CY1117367T1 (el) Αντινοηματικο νουκλεϊνικο οξυ
MY205872A (en) Pharmaceutical compositions comprising omega-3 fatty acids
NI201400078A (es) Derivados de lactamas útiles como inhibidores mutantes de idh1
BR112012027747A2 (pt) método e composição imunogênica para tratamento de neoplásia
PH12016500216A1 (en) Stable pharmaceutical composition and methods of using same
MY159396A (en) Compositions and methods for antibodies targeting complement protein c5
WO2009134487A3 (en) Optimized methods for delivery of dsrna targeting the pcsk9 gene
MX338980B (es) Metodos de tratamiento utilizando inhibidores de tlr7 y/o tlr9.
MX366925B (es) Inhibidores de ibat para el tratamiento de enfermedades hepaticas.
EA201400152A1 (ru) Микроорганизмы, продуцирующие эйкозапентаеновую кислоту, композиции, содержащие жирные кислоты, и способы их получения и применения
MX2011007188A (es) Metodos para incrementar niveles de plasmalogenos endogenos.
IN2014DN07483A (https=)
EA201290822A1 (ru) Триазолоны в качестве ингибиторов синтазы жирных кислот
EA201170294A1 (ru) Способы лечения реперфузионных повреждений
IN2014CN04634A (https=)
MX2013013891A (es) Sistema y metodo de tratamiento de agua anti-incrustaciones.
PH12014500859A1 (en) Pharmaceutical compositions comprising dgla and/or 15-hetre and methods of use thereof
IN2014KN01679A (https=)
BR112012016861A2 (pt) "método para seleção de bactéria com ação antioxidante".
MX361011B (es) Inhibidores de amida hidrolasa de ácido graso.
IN2014DN00254A (https=)
MX352071B (es) Ésteres de lactato eterificados, método de producción de los mismos y uso de los mismos para intensificar el efecto de agentes protectores de plantas.
MX2010012106A (es) Analogos de 1-metilnicotinamida.
IN2014MN02422A (https=)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal